Results 101 to 110 of about 38,515 (217)

Pathogenic Airway Bacteria and Local Immune Responses During Early‐Life Asthma‐Like Episodes

open access: yesAllergy, EarlyView.
This study investigates how Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis associate with airway immune responses during early‐life asthma‐like episodes, and compare these responses between children with and without asthma.
Mathilde Bundgaard Svendsen   +12 more
wiley   +1 more source

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

Immune Repertoire Profiling Reveals Distinct Adaptive Immune Signatures of Dampness ZHENG Across Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis

open access: yesCell Proliferation, EarlyView.
Schematic diagram for the experimental design for adaptome immune repertoire analysing Dampness ZHENG across Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis. ABSTRACT Autoimmune diseases, including psoriasis (Ps), rheumatoid arthritis (RA) and ulcerative colitis (UC), pose significant health burdens worldwide.
Lipeng Tang   +21 more
wiley   +1 more source

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara   +7 more
wiley   +1 more source

Vascularized joint‐on‐a‐chip: A paradigm shift for arthritis pathophysiology and clinical treatment

open access: yes
Rheumatology &Autoimmunity, EarlyView.
Danli Cui   +6 more
wiley   +1 more source

Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis   +4 more
wiley   +1 more source

PeakPASI as a marker of maximum psoriasis severity: a single‐center, cross‐sectional retrospective and questionnaire‐based study

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background The Psoriasis Area and Severity Index (PASI) is the standard measure for psoriasis severity but reflects only a single time point and may underestimate long‐term disease burden. To assess whether the highest‐ever recorded PASI (PeakPASI) can serve as a marker of historical disease severity and correlate with treatment burden and ...
Simran Wilkhoo   +6 more
wiley   +1 more source

Angiogenic markers in difficult-to-treat psoriatic arthritis. [PDF]

open access: yesFront Immunol
Haddad A   +10 more
europepmc   +1 more source

S1 Guideline: Therapy of generalized pustular psoriasis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy